Research Progress on Radiotherapy Combined with Immunotherapy for Associated Pneumonitis During Treatment of Non-Small Cell Lung Cancer
Anqi Zhang,1,* Fuyuan Yang,2,* Lei Gao,1,* Xiaoyan Shi,3 Jiyuan Yang1 1Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, People’s Republic of China; 2School of Basic Medicine, Health Science Center, Yangtze University, Jingzhou, People’s Repub...
Ausführliche Beschreibung
Autor*in: |
Zhang A [verfasserIn] Yang F [verfasserIn] Gao L [verfasserIn] Shi X [verfasserIn] Yang J [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2022 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Cancer Management and Research - Dove Medical Press, 2009, (2022), Seite 2469-2483 |
---|---|
Übergeordnetes Werk: |
year:2022 ; pages:2469-2483 |
Links: |
---|
Katalog-ID: |
DOAJ024247464 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ024247464 | ||
003 | DE-627 | ||
005 | 20230307073259.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230226s2022 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)DOAJ024247464 | ||
035 | |a (DE-599)DOAJ4e40e1c3408547d6b408322b1761fd6d | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RC254-282 | |
100 | 0 | |a Zhang A |e verfasserin |4 aut | |
245 | 1 | 0 | |a Research Progress on Radiotherapy Combined with Immunotherapy for Associated Pneumonitis During Treatment of Non-Small Cell Lung Cancer |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Anqi Zhang,1,* Fuyuan Yang,2,* Lei Gao,1,* Xiaoyan Shi,3 Jiyuan Yang1 1Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, People’s Republic of China; 2School of Basic Medicine, Health Science Center, Yangtze University, Jingzhou, People’s Republic of China; 3Department of Gynaecology and Obstetrics, First Affiliated Hospital of Yangtze University, Jingzhou, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jiyuan Yang, Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, People’s Republic of China, Tel +86 189 7216 1658, Fax +86 716-8062633, Email Yangjiyuanchina163.comAbstract: Radiation pneumonitis is a common and serious complication of radiotherapy for thoracic tumours. Although radiotherapy technology is constantly improving, the incidence of radiation pneumonitis is still not low, and severe cases can be life-threatening. Once radiation pneumonitis develops into radiation fibrosis (RF), it will have irreversible consequences, so it is particularly important to prevent the occurrence and development of radiation pneumonitis. Immune checkpoint inhibitors (ICIs) have rapidly altered the treatment landscape for multiple tumour types, providing unprecedented survival in some patients, especially for the treatment of non-small cell lung cancer (NSCLC). However, in addition to its remarkable curative effect, ICls may cause immune-related adverse events. The incidence of checkpoint inhibitor pneumonitis (CIP) is 3% to 5%, and its mortality rate is 10% to 17%. In addition, the incidence of CIP in NSCLC is higher than in other tumour types, reaching 7%– 13%. With the increasing use of immune checkpoint inhibitors (ICls) and thoracic radiotherapy in the treatment of patients with NSCLC, ICIs may induce delayed radiation pneumonitis in patients previously treated with radiation therapy, or radiation activation of the systemic immune system increases the toxicity of adverse reactions, which may lead to increased pulmonary toxicity and the incidence of pneumonitis. In this paper, the data about the occurrence of radiation pneumonitis, immune pneumonitis, and combined treatment and the latest related research results will be reviewed.Keywords: radiation pneumonitis, immune pneumonitis, pneumonitis after combination therapy, treatment and management of pneumonitis | ||
650 | 4 | |a radiation pneumonitis | |
650 | 4 | |a immune pneumonitis | |
650 | 4 | |a pneumonitis after combination therapy | |
650 | 4 | |a treatment and management of pneumonitis | |
653 | 0 | |a Neoplasms. Tumors. Oncology. Including cancer and carcinogens | |
700 | 0 | |a Yang F |e verfasserin |4 aut | |
700 | 0 | |a Gao L |e verfasserin |4 aut | |
700 | 0 | |a Shi X |e verfasserin |4 aut | |
700 | 0 | |a Yang J |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Cancer Management and Research |d Dove Medical Press, 2009 |g (2022), Seite 2469-2483 |w (DE-627)606030840 |w (DE-600)2508013-1 |x 11791322 |7 nnns |
773 | 1 | 8 | |g year:2022 |g pages:2469-2483 |
856 | 4 | 0 | |u https://doaj.org/article/4e40e1c3408547d6b408322b1761fd6d |z kostenfrei |
856 | 4 | 0 | |u https://www.dovepress.com/research-progress-on-radiotherapy-combined-with-immunotherapy-for-asso-peer-reviewed-fulltext-article-CMAR |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1179-1322 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |j 2022 |h 2469-2483 |
author_variant |
z a za y f yf g l gl s x sx y j yj |
---|---|
matchkey_str |
article:11791322:2022----::eerhrgesnaiteayobndihmuohrpfrsoitdnuoiidrnt |
hierarchy_sort_str |
2022 |
callnumber-subject-code |
RC |
publishDate |
2022 |
allfields |
(DE-627)DOAJ024247464 (DE-599)DOAJ4e40e1c3408547d6b408322b1761fd6d DE-627 ger DE-627 rakwb eng RC254-282 Zhang A verfasserin aut Research Progress on Radiotherapy Combined with Immunotherapy for Associated Pneumonitis During Treatment of Non-Small Cell Lung Cancer 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Anqi Zhang,1,* Fuyuan Yang,2,* Lei Gao,1,* Xiaoyan Shi,3 Jiyuan Yang1 1Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, People’s Republic of China; 2School of Basic Medicine, Health Science Center, Yangtze University, Jingzhou, People’s Republic of China; 3Department of Gynaecology and Obstetrics, First Affiliated Hospital of Yangtze University, Jingzhou, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jiyuan Yang, Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, People’s Republic of China, Tel +86 189 7216 1658, Fax +86 716-8062633, Email Yangjiyuanchina163.comAbstract: Radiation pneumonitis is a common and serious complication of radiotherapy for thoracic tumours. Although radiotherapy technology is constantly improving, the incidence of radiation pneumonitis is still not low, and severe cases can be life-threatening. Once radiation pneumonitis develops into radiation fibrosis (RF), it will have irreversible consequences, so it is particularly important to prevent the occurrence and development of radiation pneumonitis. Immune checkpoint inhibitors (ICIs) have rapidly altered the treatment landscape for multiple tumour types, providing unprecedented survival in some patients, especially for the treatment of non-small cell lung cancer (NSCLC). However, in addition to its remarkable curative effect, ICls may cause immune-related adverse events. The incidence of checkpoint inhibitor pneumonitis (CIP) is 3% to 5%, and its mortality rate is 10% to 17%. In addition, the incidence of CIP in NSCLC is higher than in other tumour types, reaching 7%– 13%. With the increasing use of immune checkpoint inhibitors (ICls) and thoracic radiotherapy in the treatment of patients with NSCLC, ICIs may induce delayed radiation pneumonitis in patients previously treated with radiation therapy, or radiation activation of the systemic immune system increases the toxicity of adverse reactions, which may lead to increased pulmonary toxicity and the incidence of pneumonitis. In this paper, the data about the occurrence of radiation pneumonitis, immune pneumonitis, and combined treatment and the latest related research results will be reviewed.Keywords: radiation pneumonitis, immune pneumonitis, pneumonitis after combination therapy, treatment and management of pneumonitis radiation pneumonitis immune pneumonitis pneumonitis after combination therapy treatment and management of pneumonitis Neoplasms. Tumors. Oncology. Including cancer and carcinogens Yang F verfasserin aut Gao L verfasserin aut Shi X verfasserin aut Yang J verfasserin aut In Cancer Management and Research Dove Medical Press, 2009 (2022), Seite 2469-2483 (DE-627)606030840 (DE-600)2508013-1 11791322 nnns year:2022 pages:2469-2483 https://doaj.org/article/4e40e1c3408547d6b408322b1761fd6d kostenfrei https://www.dovepress.com/research-progress-on-radiotherapy-combined-with-immunotherapy-for-asso-peer-reviewed-fulltext-article-CMAR kostenfrei https://doaj.org/toc/1179-1322 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2022 2469-2483 |
spelling |
(DE-627)DOAJ024247464 (DE-599)DOAJ4e40e1c3408547d6b408322b1761fd6d DE-627 ger DE-627 rakwb eng RC254-282 Zhang A verfasserin aut Research Progress on Radiotherapy Combined with Immunotherapy for Associated Pneumonitis During Treatment of Non-Small Cell Lung Cancer 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Anqi Zhang,1,* Fuyuan Yang,2,* Lei Gao,1,* Xiaoyan Shi,3 Jiyuan Yang1 1Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, People’s Republic of China; 2School of Basic Medicine, Health Science Center, Yangtze University, Jingzhou, People’s Republic of China; 3Department of Gynaecology and Obstetrics, First Affiliated Hospital of Yangtze University, Jingzhou, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jiyuan Yang, Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, People’s Republic of China, Tel +86 189 7216 1658, Fax +86 716-8062633, Email Yangjiyuanchina163.comAbstract: Radiation pneumonitis is a common and serious complication of radiotherapy for thoracic tumours. Although radiotherapy technology is constantly improving, the incidence of radiation pneumonitis is still not low, and severe cases can be life-threatening. Once radiation pneumonitis develops into radiation fibrosis (RF), it will have irreversible consequences, so it is particularly important to prevent the occurrence and development of radiation pneumonitis. Immune checkpoint inhibitors (ICIs) have rapidly altered the treatment landscape for multiple tumour types, providing unprecedented survival in some patients, especially for the treatment of non-small cell lung cancer (NSCLC). However, in addition to its remarkable curative effect, ICls may cause immune-related adverse events. The incidence of checkpoint inhibitor pneumonitis (CIP) is 3% to 5%, and its mortality rate is 10% to 17%. In addition, the incidence of CIP in NSCLC is higher than in other tumour types, reaching 7%– 13%. With the increasing use of immune checkpoint inhibitors (ICls) and thoracic radiotherapy in the treatment of patients with NSCLC, ICIs may induce delayed radiation pneumonitis in patients previously treated with radiation therapy, or radiation activation of the systemic immune system increases the toxicity of adverse reactions, which may lead to increased pulmonary toxicity and the incidence of pneumonitis. In this paper, the data about the occurrence of radiation pneumonitis, immune pneumonitis, and combined treatment and the latest related research results will be reviewed.Keywords: radiation pneumonitis, immune pneumonitis, pneumonitis after combination therapy, treatment and management of pneumonitis radiation pneumonitis immune pneumonitis pneumonitis after combination therapy treatment and management of pneumonitis Neoplasms. Tumors. Oncology. Including cancer and carcinogens Yang F verfasserin aut Gao L verfasserin aut Shi X verfasserin aut Yang J verfasserin aut In Cancer Management and Research Dove Medical Press, 2009 (2022), Seite 2469-2483 (DE-627)606030840 (DE-600)2508013-1 11791322 nnns year:2022 pages:2469-2483 https://doaj.org/article/4e40e1c3408547d6b408322b1761fd6d kostenfrei https://www.dovepress.com/research-progress-on-radiotherapy-combined-with-immunotherapy-for-asso-peer-reviewed-fulltext-article-CMAR kostenfrei https://doaj.org/toc/1179-1322 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2022 2469-2483 |
allfields_unstemmed |
(DE-627)DOAJ024247464 (DE-599)DOAJ4e40e1c3408547d6b408322b1761fd6d DE-627 ger DE-627 rakwb eng RC254-282 Zhang A verfasserin aut Research Progress on Radiotherapy Combined with Immunotherapy for Associated Pneumonitis During Treatment of Non-Small Cell Lung Cancer 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Anqi Zhang,1,* Fuyuan Yang,2,* Lei Gao,1,* Xiaoyan Shi,3 Jiyuan Yang1 1Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, People’s Republic of China; 2School of Basic Medicine, Health Science Center, Yangtze University, Jingzhou, People’s Republic of China; 3Department of Gynaecology and Obstetrics, First Affiliated Hospital of Yangtze University, Jingzhou, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jiyuan Yang, Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, People’s Republic of China, Tel +86 189 7216 1658, Fax +86 716-8062633, Email Yangjiyuanchina163.comAbstract: Radiation pneumonitis is a common and serious complication of radiotherapy for thoracic tumours. Although radiotherapy technology is constantly improving, the incidence of radiation pneumonitis is still not low, and severe cases can be life-threatening. Once radiation pneumonitis develops into radiation fibrosis (RF), it will have irreversible consequences, so it is particularly important to prevent the occurrence and development of radiation pneumonitis. Immune checkpoint inhibitors (ICIs) have rapidly altered the treatment landscape for multiple tumour types, providing unprecedented survival in some patients, especially for the treatment of non-small cell lung cancer (NSCLC). However, in addition to its remarkable curative effect, ICls may cause immune-related adverse events. The incidence of checkpoint inhibitor pneumonitis (CIP) is 3% to 5%, and its mortality rate is 10% to 17%. In addition, the incidence of CIP in NSCLC is higher than in other tumour types, reaching 7%– 13%. With the increasing use of immune checkpoint inhibitors (ICls) and thoracic radiotherapy in the treatment of patients with NSCLC, ICIs may induce delayed radiation pneumonitis in patients previously treated with radiation therapy, or radiation activation of the systemic immune system increases the toxicity of adverse reactions, which may lead to increased pulmonary toxicity and the incidence of pneumonitis. In this paper, the data about the occurrence of radiation pneumonitis, immune pneumonitis, and combined treatment and the latest related research results will be reviewed.Keywords: radiation pneumonitis, immune pneumonitis, pneumonitis after combination therapy, treatment and management of pneumonitis radiation pneumonitis immune pneumonitis pneumonitis after combination therapy treatment and management of pneumonitis Neoplasms. Tumors. Oncology. Including cancer and carcinogens Yang F verfasserin aut Gao L verfasserin aut Shi X verfasserin aut Yang J verfasserin aut In Cancer Management and Research Dove Medical Press, 2009 (2022), Seite 2469-2483 (DE-627)606030840 (DE-600)2508013-1 11791322 nnns year:2022 pages:2469-2483 https://doaj.org/article/4e40e1c3408547d6b408322b1761fd6d kostenfrei https://www.dovepress.com/research-progress-on-radiotherapy-combined-with-immunotherapy-for-asso-peer-reviewed-fulltext-article-CMAR kostenfrei https://doaj.org/toc/1179-1322 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2022 2469-2483 |
allfieldsGer |
(DE-627)DOAJ024247464 (DE-599)DOAJ4e40e1c3408547d6b408322b1761fd6d DE-627 ger DE-627 rakwb eng RC254-282 Zhang A verfasserin aut Research Progress on Radiotherapy Combined with Immunotherapy for Associated Pneumonitis During Treatment of Non-Small Cell Lung Cancer 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Anqi Zhang,1,* Fuyuan Yang,2,* Lei Gao,1,* Xiaoyan Shi,3 Jiyuan Yang1 1Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, People’s Republic of China; 2School of Basic Medicine, Health Science Center, Yangtze University, Jingzhou, People’s Republic of China; 3Department of Gynaecology and Obstetrics, First Affiliated Hospital of Yangtze University, Jingzhou, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jiyuan Yang, Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, People’s Republic of China, Tel +86 189 7216 1658, Fax +86 716-8062633, Email Yangjiyuanchina163.comAbstract: Radiation pneumonitis is a common and serious complication of radiotherapy for thoracic tumours. Although radiotherapy technology is constantly improving, the incidence of radiation pneumonitis is still not low, and severe cases can be life-threatening. Once radiation pneumonitis develops into radiation fibrosis (RF), it will have irreversible consequences, so it is particularly important to prevent the occurrence and development of radiation pneumonitis. Immune checkpoint inhibitors (ICIs) have rapidly altered the treatment landscape for multiple tumour types, providing unprecedented survival in some patients, especially for the treatment of non-small cell lung cancer (NSCLC). However, in addition to its remarkable curative effect, ICls may cause immune-related adverse events. The incidence of checkpoint inhibitor pneumonitis (CIP) is 3% to 5%, and its mortality rate is 10% to 17%. In addition, the incidence of CIP in NSCLC is higher than in other tumour types, reaching 7%– 13%. With the increasing use of immune checkpoint inhibitors (ICls) and thoracic radiotherapy in the treatment of patients with NSCLC, ICIs may induce delayed radiation pneumonitis in patients previously treated with radiation therapy, or radiation activation of the systemic immune system increases the toxicity of adverse reactions, which may lead to increased pulmonary toxicity and the incidence of pneumonitis. In this paper, the data about the occurrence of radiation pneumonitis, immune pneumonitis, and combined treatment and the latest related research results will be reviewed.Keywords: radiation pneumonitis, immune pneumonitis, pneumonitis after combination therapy, treatment and management of pneumonitis radiation pneumonitis immune pneumonitis pneumonitis after combination therapy treatment and management of pneumonitis Neoplasms. Tumors. Oncology. Including cancer and carcinogens Yang F verfasserin aut Gao L verfasserin aut Shi X verfasserin aut Yang J verfasserin aut In Cancer Management and Research Dove Medical Press, 2009 (2022), Seite 2469-2483 (DE-627)606030840 (DE-600)2508013-1 11791322 nnns year:2022 pages:2469-2483 https://doaj.org/article/4e40e1c3408547d6b408322b1761fd6d kostenfrei https://www.dovepress.com/research-progress-on-radiotherapy-combined-with-immunotherapy-for-asso-peer-reviewed-fulltext-article-CMAR kostenfrei https://doaj.org/toc/1179-1322 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2022 2469-2483 |
allfieldsSound |
(DE-627)DOAJ024247464 (DE-599)DOAJ4e40e1c3408547d6b408322b1761fd6d DE-627 ger DE-627 rakwb eng RC254-282 Zhang A verfasserin aut Research Progress on Radiotherapy Combined with Immunotherapy for Associated Pneumonitis During Treatment of Non-Small Cell Lung Cancer 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Anqi Zhang,1,* Fuyuan Yang,2,* Lei Gao,1,* Xiaoyan Shi,3 Jiyuan Yang1 1Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, People’s Republic of China; 2School of Basic Medicine, Health Science Center, Yangtze University, Jingzhou, People’s Republic of China; 3Department of Gynaecology and Obstetrics, First Affiliated Hospital of Yangtze University, Jingzhou, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jiyuan Yang, Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, People’s Republic of China, Tel +86 189 7216 1658, Fax +86 716-8062633, Email Yangjiyuanchina163.comAbstract: Radiation pneumonitis is a common and serious complication of radiotherapy for thoracic tumours. Although radiotherapy technology is constantly improving, the incidence of radiation pneumonitis is still not low, and severe cases can be life-threatening. Once radiation pneumonitis develops into radiation fibrosis (RF), it will have irreversible consequences, so it is particularly important to prevent the occurrence and development of radiation pneumonitis. Immune checkpoint inhibitors (ICIs) have rapidly altered the treatment landscape for multiple tumour types, providing unprecedented survival in some patients, especially for the treatment of non-small cell lung cancer (NSCLC). However, in addition to its remarkable curative effect, ICls may cause immune-related adverse events. The incidence of checkpoint inhibitor pneumonitis (CIP) is 3% to 5%, and its mortality rate is 10% to 17%. In addition, the incidence of CIP in NSCLC is higher than in other tumour types, reaching 7%– 13%. With the increasing use of immune checkpoint inhibitors (ICls) and thoracic radiotherapy in the treatment of patients with NSCLC, ICIs may induce delayed radiation pneumonitis in patients previously treated with radiation therapy, or radiation activation of the systemic immune system increases the toxicity of adverse reactions, which may lead to increased pulmonary toxicity and the incidence of pneumonitis. In this paper, the data about the occurrence of radiation pneumonitis, immune pneumonitis, and combined treatment and the latest related research results will be reviewed.Keywords: radiation pneumonitis, immune pneumonitis, pneumonitis after combination therapy, treatment and management of pneumonitis radiation pneumonitis immune pneumonitis pneumonitis after combination therapy treatment and management of pneumonitis Neoplasms. Tumors. Oncology. Including cancer and carcinogens Yang F verfasserin aut Gao L verfasserin aut Shi X verfasserin aut Yang J verfasserin aut In Cancer Management and Research Dove Medical Press, 2009 (2022), Seite 2469-2483 (DE-627)606030840 (DE-600)2508013-1 11791322 nnns year:2022 pages:2469-2483 https://doaj.org/article/4e40e1c3408547d6b408322b1761fd6d kostenfrei https://www.dovepress.com/research-progress-on-radiotherapy-combined-with-immunotherapy-for-asso-peer-reviewed-fulltext-article-CMAR kostenfrei https://doaj.org/toc/1179-1322 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2022 2469-2483 |
language |
English |
source |
In Cancer Management and Research (2022), Seite 2469-2483 year:2022 pages:2469-2483 |
sourceStr |
In Cancer Management and Research (2022), Seite 2469-2483 year:2022 pages:2469-2483 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
radiation pneumonitis immune pneumonitis pneumonitis after combination therapy treatment and management of pneumonitis Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
isfreeaccess_bool |
true |
container_title |
Cancer Management and Research |
authorswithroles_txt_mv |
Zhang A @@aut@@ Yang F @@aut@@ Gao L @@aut@@ Shi X @@aut@@ Yang J @@aut@@ |
publishDateDaySort_date |
2022-01-01T00:00:00Z |
hierarchy_top_id |
606030840 |
id |
DOAJ024247464 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ024247464</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307073259.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ024247464</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ4e40e1c3408547d6b408322b1761fd6d</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Zhang A</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Research Progress on Radiotherapy Combined with Immunotherapy for Associated Pneumonitis During Treatment of Non-Small Cell Lung Cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Anqi Zhang,1,&ast; Fuyuan Yang,2,&ast; Lei Gao,1,&ast; Xiaoyan Shi,3 Jiyuan Yang1 1Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, People’s Republic of China; 2School of Basic Medicine, Health Science Center, Yangtze University, Jingzhou, People’s Republic of China; 3Department of Gynaecology and Obstetrics, First Affiliated Hospital of Yangtze University, Jingzhou, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Jiyuan Yang, Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, People’s Republic of China, Tel +86 189 7216 1658, Fax +86 716-8062633, Email Yangjiyuanchina163.comAbstract: Radiation pneumonitis is a common and serious complication of radiotherapy for thoracic tumours. Although radiotherapy technology is constantly improving, the incidence of radiation pneumonitis is still not low, and severe cases can be life-threatening. Once radiation pneumonitis develops into radiation fibrosis (RF), it will have irreversible consequences, so it is particularly important to prevent the occurrence and development of radiation pneumonitis. Immune checkpoint inhibitors (ICIs) have rapidly altered the treatment landscape for multiple tumour types, providing unprecedented survival in some patients, especially for the treatment of non-small cell lung cancer (NSCLC). However, in addition to its remarkable curative effect, ICls may cause immune-related adverse events. The incidence of checkpoint inhibitor pneumonitis (CIP) is 3% to 5%, and its mortality rate is 10% to 17%. In addition, the incidence of CIP in NSCLC is higher than in other tumour types, reaching 7%– 13%. With the increasing use of immune checkpoint inhibitors (ICls) and thoracic radiotherapy in the treatment of patients with NSCLC, ICIs may induce delayed radiation pneumonitis in patients previously treated with radiation therapy, or radiation activation of the systemic immune system increases the toxicity of adverse reactions, which may lead to increased pulmonary toxicity and the incidence of pneumonitis. In this paper, the data about the occurrence of radiation pneumonitis, immune pneumonitis, and combined treatment and the latest related research results will be reviewed.Keywords: radiation pneumonitis, immune pneumonitis, pneumonitis after combination therapy, treatment and management of pneumonitis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">radiation pneumonitis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immune pneumonitis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">pneumonitis after combination therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">treatment and management of pneumonitis</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yang F</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gao L</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shi X</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yang J</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Cancer Management and Research</subfield><subfield code="d">Dove Medical Press, 2009</subfield><subfield code="g">(2022), Seite 2469-2483</subfield><subfield code="w">(DE-627)606030840</subfield><subfield code="w">(DE-600)2508013-1</subfield><subfield code="x">11791322</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2022</subfield><subfield code="g">pages:2469-2483</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/4e40e1c3408547d6b408322b1761fd6d</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.dovepress.com/research-progress-on-radiotherapy-combined-with-immunotherapy-for-asso-peer-reviewed-fulltext-article-CMAR</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1179-1322</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2022</subfield><subfield code="h">2469-2483</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Zhang A |
spellingShingle |
Zhang A misc RC254-282 misc radiation pneumonitis misc immune pneumonitis misc pneumonitis after combination therapy misc treatment and management of pneumonitis misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens Research Progress on Radiotherapy Combined with Immunotherapy for Associated Pneumonitis During Treatment of Non-Small Cell Lung Cancer |
authorStr |
Zhang A |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)606030840 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
RC254-282 |
illustrated |
Not Illustrated |
issn |
11791322 |
topic_title |
RC254-282 Research Progress on Radiotherapy Combined with Immunotherapy for Associated Pneumonitis During Treatment of Non-Small Cell Lung Cancer radiation pneumonitis immune pneumonitis pneumonitis after combination therapy treatment and management of pneumonitis |
topic |
misc RC254-282 misc radiation pneumonitis misc immune pneumonitis misc pneumonitis after combination therapy misc treatment and management of pneumonitis misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
topic_unstemmed |
misc RC254-282 misc radiation pneumonitis misc immune pneumonitis misc pneumonitis after combination therapy misc treatment and management of pneumonitis misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
topic_browse |
misc RC254-282 misc radiation pneumonitis misc immune pneumonitis misc pneumonitis after combination therapy misc treatment and management of pneumonitis misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Cancer Management and Research |
hierarchy_parent_id |
606030840 |
hierarchy_top_title |
Cancer Management and Research |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)606030840 (DE-600)2508013-1 |
title |
Research Progress on Radiotherapy Combined with Immunotherapy for Associated Pneumonitis During Treatment of Non-Small Cell Lung Cancer |
ctrlnum |
(DE-627)DOAJ024247464 (DE-599)DOAJ4e40e1c3408547d6b408322b1761fd6d |
title_full |
Research Progress on Radiotherapy Combined with Immunotherapy for Associated Pneumonitis During Treatment of Non-Small Cell Lung Cancer |
author_sort |
Zhang A |
journal |
Cancer Management and Research |
journalStr |
Cancer Management and Research |
callnumber-first-code |
R |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2022 |
contenttype_str_mv |
txt |
container_start_page |
2469 |
author_browse |
Zhang A Yang F Gao L Shi X Yang J |
class |
RC254-282 |
format_se |
Elektronische Aufsätze |
author-letter |
Zhang A |
author2-role |
verfasserin |
title_sort |
research progress on radiotherapy combined with immunotherapy for associated pneumonitis during treatment of non-small cell lung cancer |
callnumber |
RC254-282 |
title_auth |
Research Progress on Radiotherapy Combined with Immunotherapy for Associated Pneumonitis During Treatment of Non-Small Cell Lung Cancer |
abstract |
Anqi Zhang,1,* Fuyuan Yang,2,* Lei Gao,1,* Xiaoyan Shi,3 Jiyuan Yang1 1Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, People’s Republic of China; 2School of Basic Medicine, Health Science Center, Yangtze University, Jingzhou, People’s Republic of China; 3Department of Gynaecology and Obstetrics, First Affiliated Hospital of Yangtze University, Jingzhou, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jiyuan Yang, Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, People’s Republic of China, Tel +86 189 7216 1658, Fax +86 716-8062633, Email Yangjiyuanchina163.comAbstract: Radiation pneumonitis is a common and serious complication of radiotherapy for thoracic tumours. Although radiotherapy technology is constantly improving, the incidence of radiation pneumonitis is still not low, and severe cases can be life-threatening. Once radiation pneumonitis develops into radiation fibrosis (RF), it will have irreversible consequences, so it is particularly important to prevent the occurrence and development of radiation pneumonitis. Immune checkpoint inhibitors (ICIs) have rapidly altered the treatment landscape for multiple tumour types, providing unprecedented survival in some patients, especially for the treatment of non-small cell lung cancer (NSCLC). However, in addition to its remarkable curative effect, ICls may cause immune-related adverse events. The incidence of checkpoint inhibitor pneumonitis (CIP) is 3% to 5%, and its mortality rate is 10% to 17%. In addition, the incidence of CIP in NSCLC is higher than in other tumour types, reaching 7%– 13%. With the increasing use of immune checkpoint inhibitors (ICls) and thoracic radiotherapy in the treatment of patients with NSCLC, ICIs may induce delayed radiation pneumonitis in patients previously treated with radiation therapy, or radiation activation of the systemic immune system increases the toxicity of adverse reactions, which may lead to increased pulmonary toxicity and the incidence of pneumonitis. In this paper, the data about the occurrence of radiation pneumonitis, immune pneumonitis, and combined treatment and the latest related research results will be reviewed.Keywords: radiation pneumonitis, immune pneumonitis, pneumonitis after combination therapy, treatment and management of pneumonitis |
abstractGer |
Anqi Zhang,1,* Fuyuan Yang,2,* Lei Gao,1,* Xiaoyan Shi,3 Jiyuan Yang1 1Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, People’s Republic of China; 2School of Basic Medicine, Health Science Center, Yangtze University, Jingzhou, People’s Republic of China; 3Department of Gynaecology and Obstetrics, First Affiliated Hospital of Yangtze University, Jingzhou, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jiyuan Yang, Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, People’s Republic of China, Tel +86 189 7216 1658, Fax +86 716-8062633, Email Yangjiyuanchina163.comAbstract: Radiation pneumonitis is a common and serious complication of radiotherapy for thoracic tumours. Although radiotherapy technology is constantly improving, the incidence of radiation pneumonitis is still not low, and severe cases can be life-threatening. Once radiation pneumonitis develops into radiation fibrosis (RF), it will have irreversible consequences, so it is particularly important to prevent the occurrence and development of radiation pneumonitis. Immune checkpoint inhibitors (ICIs) have rapidly altered the treatment landscape for multiple tumour types, providing unprecedented survival in some patients, especially for the treatment of non-small cell lung cancer (NSCLC). However, in addition to its remarkable curative effect, ICls may cause immune-related adverse events. The incidence of checkpoint inhibitor pneumonitis (CIP) is 3% to 5%, and its mortality rate is 10% to 17%. In addition, the incidence of CIP in NSCLC is higher than in other tumour types, reaching 7%– 13%. With the increasing use of immune checkpoint inhibitors (ICls) and thoracic radiotherapy in the treatment of patients with NSCLC, ICIs may induce delayed radiation pneumonitis in patients previously treated with radiation therapy, or radiation activation of the systemic immune system increases the toxicity of adverse reactions, which may lead to increased pulmonary toxicity and the incidence of pneumonitis. In this paper, the data about the occurrence of radiation pneumonitis, immune pneumonitis, and combined treatment and the latest related research results will be reviewed.Keywords: radiation pneumonitis, immune pneumonitis, pneumonitis after combination therapy, treatment and management of pneumonitis |
abstract_unstemmed |
Anqi Zhang,1,* Fuyuan Yang,2,* Lei Gao,1,* Xiaoyan Shi,3 Jiyuan Yang1 1Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, People’s Republic of China; 2School of Basic Medicine, Health Science Center, Yangtze University, Jingzhou, People’s Republic of China; 3Department of Gynaecology and Obstetrics, First Affiliated Hospital of Yangtze University, Jingzhou, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jiyuan Yang, Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, People’s Republic of China, Tel +86 189 7216 1658, Fax +86 716-8062633, Email Yangjiyuanchina163.comAbstract: Radiation pneumonitis is a common and serious complication of radiotherapy for thoracic tumours. Although radiotherapy technology is constantly improving, the incidence of radiation pneumonitis is still not low, and severe cases can be life-threatening. Once radiation pneumonitis develops into radiation fibrosis (RF), it will have irreversible consequences, so it is particularly important to prevent the occurrence and development of radiation pneumonitis. Immune checkpoint inhibitors (ICIs) have rapidly altered the treatment landscape for multiple tumour types, providing unprecedented survival in some patients, especially for the treatment of non-small cell lung cancer (NSCLC). However, in addition to its remarkable curative effect, ICls may cause immune-related adverse events. The incidence of checkpoint inhibitor pneumonitis (CIP) is 3% to 5%, and its mortality rate is 10% to 17%. In addition, the incidence of CIP in NSCLC is higher than in other tumour types, reaching 7%– 13%. With the increasing use of immune checkpoint inhibitors (ICls) and thoracic radiotherapy in the treatment of patients with NSCLC, ICIs may induce delayed radiation pneumonitis in patients previously treated with radiation therapy, or radiation activation of the systemic immune system increases the toxicity of adverse reactions, which may lead to increased pulmonary toxicity and the incidence of pneumonitis. In this paper, the data about the occurrence of radiation pneumonitis, immune pneumonitis, and combined treatment and the latest related research results will be reviewed.Keywords: radiation pneumonitis, immune pneumonitis, pneumonitis after combination therapy, treatment and management of pneumonitis |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
title_short |
Research Progress on Radiotherapy Combined with Immunotherapy for Associated Pneumonitis During Treatment of Non-Small Cell Lung Cancer |
url |
https://doaj.org/article/4e40e1c3408547d6b408322b1761fd6d https://www.dovepress.com/research-progress-on-radiotherapy-combined-with-immunotherapy-for-asso-peer-reviewed-fulltext-article-CMAR https://doaj.org/toc/1179-1322 |
remote_bool |
true |
author2 |
Yang F Gao L Shi X Yang J |
author2Str |
Yang F Gao L Shi X Yang J |
ppnlink |
606030840 |
callnumber-subject |
RC - Internal Medicine |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
callnumber-a |
RC254-282 |
up_date |
2024-07-03T21:59:58.105Z |
_version_ |
1803596855357997056 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ024247464</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307073259.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ024247464</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ4e40e1c3408547d6b408322b1761fd6d</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Zhang A</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Research Progress on Radiotherapy Combined with Immunotherapy for Associated Pneumonitis During Treatment of Non-Small Cell Lung Cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Anqi Zhang,1,&ast; Fuyuan Yang,2,&ast; Lei Gao,1,&ast; Xiaoyan Shi,3 Jiyuan Yang1 1Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, People’s Republic of China; 2School of Basic Medicine, Health Science Center, Yangtze University, Jingzhou, People’s Republic of China; 3Department of Gynaecology and Obstetrics, First Affiliated Hospital of Yangtze University, Jingzhou, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Jiyuan Yang, Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, People’s Republic of China, Tel +86 189 7216 1658, Fax +86 716-8062633, Email Yangjiyuanchina163.comAbstract: Radiation pneumonitis is a common and serious complication of radiotherapy for thoracic tumours. Although radiotherapy technology is constantly improving, the incidence of radiation pneumonitis is still not low, and severe cases can be life-threatening. Once radiation pneumonitis develops into radiation fibrosis (RF), it will have irreversible consequences, so it is particularly important to prevent the occurrence and development of radiation pneumonitis. Immune checkpoint inhibitors (ICIs) have rapidly altered the treatment landscape for multiple tumour types, providing unprecedented survival in some patients, especially for the treatment of non-small cell lung cancer (NSCLC). However, in addition to its remarkable curative effect, ICls may cause immune-related adverse events. The incidence of checkpoint inhibitor pneumonitis (CIP) is 3% to 5%, and its mortality rate is 10% to 17%. In addition, the incidence of CIP in NSCLC is higher than in other tumour types, reaching 7%– 13%. With the increasing use of immune checkpoint inhibitors (ICls) and thoracic radiotherapy in the treatment of patients with NSCLC, ICIs may induce delayed radiation pneumonitis in patients previously treated with radiation therapy, or radiation activation of the systemic immune system increases the toxicity of adverse reactions, which may lead to increased pulmonary toxicity and the incidence of pneumonitis. In this paper, the data about the occurrence of radiation pneumonitis, immune pneumonitis, and combined treatment and the latest related research results will be reviewed.Keywords: radiation pneumonitis, immune pneumonitis, pneumonitis after combination therapy, treatment and management of pneumonitis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">radiation pneumonitis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immune pneumonitis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">pneumonitis after combination therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">treatment and management of pneumonitis</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yang F</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gao L</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shi X</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yang J</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Cancer Management and Research</subfield><subfield code="d">Dove Medical Press, 2009</subfield><subfield code="g">(2022), Seite 2469-2483</subfield><subfield code="w">(DE-627)606030840</subfield><subfield code="w">(DE-600)2508013-1</subfield><subfield code="x">11791322</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2022</subfield><subfield code="g">pages:2469-2483</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/4e40e1c3408547d6b408322b1761fd6d</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.dovepress.com/research-progress-on-radiotherapy-combined-with-immunotherapy-for-asso-peer-reviewed-fulltext-article-CMAR</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1179-1322</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2022</subfield><subfield code="h">2469-2483</subfield></datafield></record></collection>
|
score |
7.4002905 |